Chemically Programmed Immunity

化学编程免疫

• 批准号: 8318204
• 负责人: CARLOS F BARBAS
• 金额: $ 94万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-30 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8318204
• 关键词: Antibodies; Biomedical Research; Cells; Chemicals; Development; Disease; Flu virus; Goals; HIV-1; Immune; Immune system; Immunity; Immunoglobulins; Infection prevention; Learning; Natural Immunity; Receptor Signaling; Scientist; T-Lymphocyte; Therapeutic; Toll-like receptors; Vaccines; Virus; abstracting; acquired immunity; arm; cancer therapy; flu; insight; interest; macrophage; meetings; novel; novel strategies; novel vaccines; pathogen; pill; programs; prophylactic; response; tumor

DESCRIPTION Abstract: Imagine calling T-cells, macrophages, and antibodies into action by taking a simple pill that instantaneously programs both adaptive and innate arms of the immune system to attack a tumor or virus, preventing infection and halting disease. Such an approach could meet major unmet challenges in biomedical research and therapy. My goal is to develop novel approaches that allow innate and acquired immunity to be purposefully targeted to pathogens of interest. These studies build on recently revealed mechanisms of Toll-like receptor signaling, ideas concerning approaches of targeting their sensing abilities to pathogens of defined interest and insights gained from our own invention of chemically programmed antibodies. Ultimately, these studies will allow scientists to program a variety of immune cells and responses to attack pathogens of interest using a variety of mechanisms. We will apply these results to studies in cancer therapy. Furthermore, we will explore novel approaches that should allow for circulating immunoglobulins induced with covalent vaccines to be programmed to inhibit HIV-1 and flu virus entry. The vaccines that result from these studies may be of both prophylactic and therapeutics utility. I will develop novel chemical approaches aimed at learning how to purposefully target innate immunity, T- cells, and macrophages to defined pathogens. I will apply these developments to create new cancer therapies. I will develop a novel approach to orally available chemically programmed immunity. I will apply developments in orally available chemically programmed immunity towards new vaccine strategies for HIV-1 and flu.

描述 抽象的： 想象一下，将T细胞，巨噬细胞和抗体称为采取简单的药丸，该药丸即时对免疫系统的适应性和先天臂进行编程，以攻击肿瘤或病毒，以防止感染和停止疾病。这种方法可以应对生物医学研究和治疗中的主要尚未满足的挑战。我的目标是开发新颖的方法，以使先天和获得的免疫力有目的地针对感兴趣的病原体。这些研究基于最近揭示了类似Toll样受体信号传导的机制，即有关将其感应能力靶向定义兴趣的方法的想法，并从我们自身对化学程序化抗体的发明中获得的见解。最终，这些研究将使科学家能够使用多种机制对各种免疫细胞进行编程和对攻击感兴趣的病原体的反应。我们将将这些结果应用于癌症治疗的研究。此外，我们将探索新的方法，这些方法应允许用共价疫苗诱导的循环免疫球蛋白进行编程以抑制HIV-1和流感病毒的进入。这些研究引起的疫苗可能是预防性和治疗性效用。我将开发出旨在学习如何将先天免疫，T细胞和巨噬细胞靶向定义的病原体的新型化学方法。 我将应用这些发展来创建新的癌症疗法。 我将开发出一种新型的口服化学编程免疫力。我将在口服的化学程序免疫中应用开发项目，以实现HIV-1和流感的新疫苗策略。